New weight management drugs could be used to create a global metabolic health revolution and improve longevity, if investment ...

The foundation behind Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, will invest €80 million ($93 million) ...

New and disturbing concerns about fake GLP-1 drugs are cited in a letter sent to the FDA by Tennessee officials, including Sen. Marsha Blackburn.

HONG KONG SAR - Media OutReach Newswire - 17 July 2025 - Cyberport successfully hosted the "AI x Data Forum" today. Centered on the theme "AI in Action, Data at the Core: Unlocking Infinite Potential" ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

There's nothing preventing patients from lying when asked about eating disorders as part of the telehealth screening and without access to a patient's health records, it can be difficult for medical ...

STORY: "Absolutely unacceptable and unjustified."That was the reaction from EU ministers to a 30% tariff on European goods ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Markets enter the week on edge as Q2 earnings season kicks off with heavyweight banks and global blue chips. Investors will ...

On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.

Overview of Obesity Treatment MarketThe global Obesity Treatment Market is valued at USD 22.2 Billion in 2024 and is projected to reach a value of USD 194.1 Billion by 2035 at a CAGR (Compound Annual ...